Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAllain-Thibeault FerhatSBStéfania BramantiJSJaime Sanz

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows thiotepa dose influences overall survival and graft versus host disease in acute myeloid leukemia.

Key Points

  • Severe graft versus host disease risk increases with higher thiotepa doses, impacting survival.
  • Overall survival rates at 2 years were 71.1% for TBF-MAC and 59.3% for TBF-RIC groups.
  • Retrospective analysis based on the EBMT registry data from 2010 to 2022.
  • Lower thiotepa doses might be preferable to reduce adverse effects and improve outcomes.

Cite This Study

Ferhat et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db44https://doi.org/10.1182/blood-2025-5980
View Full Paper
Ask AI
Bookmark
Share